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Abstract
CONTEXT—Opioid use and abuse have increased dramatically in recent years, particularly 
among women.
OBJECTIVES—We conducted a systematic review to evaluate the association between prenatal 
opioid use and congenital malformations.
DATA SOURCES—We searched Medline and Embase for studies published from 1946 to 2016 
and reviewed reference lists to identify additional relevant studies.
STUDY SELECTION—We included studies that were full-text journal articles and reported the 
results of original epidemiologic research on prenatal opioid exposure and congenital 
malformations. We assessed study eligibility in multiple phases using a standardized, duplicate 
review process.
DATA EXTRACTION—Data on study characteristics, opioid exposure, timing of exposure 
during pregnancy, congenital malformations (collectively or as individual subtypes), length of 
follow-up, and main findings were extracted from eligible studies.
RESULTS—Of the 68 studies that met our inclusion criteria, 46 had an unexposed comparison 
group; of those, 30 performed statistical tests to measure associations between maternal opioid use 
during pregnancy and congenital malformations. Seventeen of these (10 of 12 case-control and 7 
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of 18 cohort studies) documented statistically significant positive associations. Among the case-
control studies, associations with oral clefts and ventricular septal defects/atrial septal defects were 
the most frequently reported specific malformations. Among the cohort studies, clubfoot was the 
most frequently reported specific malformation.
LIMITATIONS—Variabilities in study design, poor study quality, and weaknesses with outcome 
and exposure measurement.
CONCLUSIONS—Uncertainty remains regarding the teratogenicity of opioids; a careful 
assessment of risks and benefits is warranted when considering opioid treatment for women of 
reproductive age.
Opioids are powerful substances that bind to opioid receptors in the brain and body and are 
capable of producing numerous physiologic effects, including reduced perception of pain 
and euphoria.1 Some prescription opioids (eg, methadone and buprenorphine) are also used 
to treat opioid use disorder (OUD). The use, misuse, and abuse of prescription and illicit 
opioids in the United States have increased dramatically in recent years, particularly among 
women. Between 1999 and 2010, women experienced a >400% increase in prescription 
opioid overdose deaths, and for every overdose death, there were 30 more opioid misuse/
abuse emergency department visits.2
Overprescribing practices appear to be driving the epidemic. In 2012 alone, prescribers 
wrote an estimated 259 million opioid prescriptions nationwide, which is equivalent to 82.5 
opioid prescriptions per 100 persons in the United States.3 Among insured, reproductive-
aged women, on average, more than one-quarter filled a prescription for an opioid 
medication each year during 2008 to 2012.4 Rates of illicit opioid use, including heroin 
abuse and dependence, are also increasing. From 2002 to 2013, the incidence of women 
reporting past-year abuse or dependence on heroin increased 100%.5
Opioid use is high among pregnant women in the United States as well, with an estimated 
14% to 22% of women receiving an opioid prescription during pregnancy.6,7 From 1998 to 
2011, the prevalence of opioid abuse or dependence among pregnant women during 
hospitalizations for delivery increased 127%.8 The high rates of prescription and illicit 
opioid use are a significant public health concern, not only for women, but also for their 
infants. Opioids have the ability to cross placental and blood-brain barriers, thereby posing 
risks for fetuses and newborns who are exposed to such drugs in utero.9 Spontaneous 
abortion, premature rupture of membranes, preeclampsia, abruption placentae, and fetal 
death are all potential obstetric complications of prenatal opioid exposure.10 Adverse 
neonatal outcomes that have been associated with opioid use during pregnancy include 
preterm birth,11–19 small for gestational age,15,19–21 lower birth weight,10,13,14,18,19,21,22 
reduced head circumference,17,23–25 and sudden infant death.26–28 Neonatal abstinence 
syndrome (NAS) is another adverse outcome commonly reported in newborns prenatally 
exposed to opioids. The incidence of NAS diagnoses increased nearly fivefold in the United 
States during 2000 to 2012, which suggests an increasing number of opioid-exposed 
pregnancies.29 Neurodevelopmental outcomes of prenatally exposed infants are an 
additional area of concern, because a recent meta-analysis reported significant impairments 
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in cognitive, psychomotor, and observed behavioral outcomes in infants and preschool-aged 
children with chronic intrauterine opioid exposure.30,31
The potential teratogenic effects of maternal opioid use during pregnancy are also an area of 
great public health concern. Congenital malformations are serious, often costly medical 
conditions that can cause lifelong challenges. They are a leading cause of infant death in the 
United States, accounting for 20% of all deaths during the first year of life.32 Furthermore, 
an estimated $2.6 billion was spent in 2004 in total hospital costs for children and adults 
with congenital malformations, and it is likely that costs have increased since that time.33 
Congenital malformations can occur at any time during pregnancy, but the first trimester is 
typically the most vulnerable period. Some malformations can be prevented by identifying 
modifiable risk factors, such as exposure to teratogenic substances, during this critical 
period. Two recent studies funded by the Centers for Disease Control and Prevention have 
linked opioid use during early pregnancy to congenital malformations.34,35 These studies 
report a twofold increased risk for some congenital heart defects, neural tube defects, and 
gastroschisis and highlight the need for a review of the entire body of evidence related to this 
critical, yet less discussed, public health concern.
The objective of this report was to systematically review the available literature on maternal 
opioid use during pregnancy and congenital malformations.
METHODS
Data Sources
We identified relevant articles by searching electronic databases, using a combination of 
opioid- and congenital malformation–related Medical Subject Headings search terms and 
keywords (Supplemental Materials) for human studies published in the English language. 
We used the Ovid platform (Ovid Technologies, Inc) to conduct literature searches of 
Medline (1946 to present) and Embase (1988 to 2016, week 7) for publications indexed 
through February 19, 2016. We combined and deduplicated the results into a single EndNote 
X7.5 (Thomson Reuters) library. In addition, we reviewed the reference lists of included 
publications to identify additional relevant studies.
Study Selection
We included publications in this review if they: (1) were full-text journal articles (we 
excluded abstracts); (2) reported the results of original epidemiologic research (we excluded 
case reports, case series, editorials without original data, commentaries without original 
data, review papers, clinical guidelines, small descriptive studies [<100 participants], and 
duplicate reports); (3) reported on exposure to opioids during pregnancy (we excluded 
reports based on exposures during labor/delivery only); and (4) reported the presence or 
absence of congenital malformations (collectively or as individual subtypes) as an outcome. 
For simplicity, hereafter, we refer to distinct publications as “studies” and note overlapping 
data (when known) in Table 1.
We assessed study eligibility in 3 phases, title review, abstract review, and full-text review, 
using standardized, duplicate review by coauthor pairs. If either reviewer specified that the 
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study should be included during any of the review phases, it was flagged to be included in 
the next phase of review. If both reviewers independently determined that a study should be 
excluded, it was excluded without additional review. During the review phases, we excluded 
any duplicate studies that were missed in the EndNote deduplication process.
To systematically extract data, we identified data items of interest and created an electronic 
data extraction form. We then pilot tested and revised the extraction form as needed. During 
the data extraction phase, the studies were divided between 2 reviewers. After independently 
extracting data from their assigned studies, the reviewers exchanged studies and checked the 
extracted data for completeness. Discrepancies were resolved through discussion and, when 
necessary, by consulting additional coauthor reviewers.
Study Quality Assessment
We assessed the quality of observational studies included in this review by using modified 
versions of the (1) Methodological Evaluation of Observational Research–Observational 
Studies of Risk Factors of Chronic Diseases criteria for studies with comparison groups and 
(2) Methodological Evaluation of Observational Research–Observational Studies of 
Population Incidence or Prevalence of Chronic Diseases criteria for large descriptive 
studies.90 We selected these validated quality assessment checklists because of their ability 
to distinguish between the external and internal validity of study findings.90 The specific 
study qualities that we assessed included generalizability, sampling method, sampling frame 
selection bias, response rate, outcome measurement, exposure measurement, exposure 
intensity/dose, information bias, differential data collection, differential measurement, and 
confounding. In the absence of established definitions, we defined “gold standard” methods 
of assessing outcomes and exposures as outcomes measured in a standard, valid, and reliable 
way and precise and/or accurate assessment of exposures, respectively.
RESULTS
Our searches of the Medline and Embase databases yielded a total of 20114 potentially 
relevant publications, whose titles and abstracts were reviewed (Fig 1). Duplicates and 
studies deemed ineligible were excluded, leaving a total of 890 studies to be examined in 
detail. Of the 890 studies reviewed, 62 met our inclusion criteria. We identified an additional 
6 relevant studies by reviewing the reference lists of these eligible studies. We summarize 
the characteristics of the 68 studies included in this review in Table 1.
Studies With an Unexposed Comparison Group
We included 46 studies with a comparison group unexposed to opioids during pregnancy 
that investigated associations between prenatal opioid exposure and congenital 
malformations; 13 were case-control studies and 33 were cohort studies.
Case-Control Studies—The majority (8 of 13) of the included case-control studies were 
published from 1975 through 1998 (Table 2), before the current opioid epidemic39,40,69–73,89 
Seven opioid exposure34,35,39,70,71,79,83; of these, 2 studies also assessed congenital 
malformations associated with codeine and/or oxycodone exposure.35,39 Five studies 
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focused specifically on codeine exposures.40, 69,72,73,89 Most (7 of 13) studies did not 
specify the indications for maternal opioid exposure, and one of the included studies did not 
present risk estimates of congenital malformations in infants exposed to opioids.79
Ten case-control studies reported statistically significant positive associations between 
opioid exposure during pregnancy and congenital malformations.34,35,39,40,43,69–71,83,89 
Studies evaluating opioid exposure in aggregate found that use during early pregnancy was 
associated with an increased risk of congenital malformations overall,39 as well as heart 
malformations overall,34 inguinal hernia with/without obstruction,39 ventricular septal 
defects (VSD)/atrial septal defects,34,39 oral clefts,39,70,71 dislocated hip/musculoskeletal 
defects,39 spina bifida,34,35 tetralogy of Fallot,34 hypoplastic left heart syndrome,34 right 
ventricular outflow tract obstruction defects,34 pulmonary valve stenosis,34 atrioventricular 
septal defects,34 isolated clubfoot,83 neural tube defects,35 and other heart and circulatory 
defects.39 Bracken and Holford39 also reported that exposure to opioids for the first time 
during the second trimester was associated with alimentary tract defects.
Eight case-control studies evaluated exposures to specific types of 
opioids.35,39,40,43,69,72,73,89 Of these, 4 studies found codeine to be associated with an 
increased risk of: congenital malformations overall,39 heart malformations overall,40,69,89 
VSD,89 and double-outlet right ventricle defects.89 In 2 studies by Shaw et al,72,73 codeine 
use in pregnancy was not significantly associated with congenital cardiac malformations or 
neural tube defects. Bracken40 initially reported an increased prevalence of heart 
malformations in codeine-exposed infants compared with unexposed infants; however, when 
Bracken40 recomputed the prevalence ratios to include infants with other malformations as 
the controls, the association was no longer statistically significant. Yazdy et al35 reported an 
increased risk of spina bifida with noncodeine opioid exposures. And Daud et al43 found an 
increased risk for respiratory malformations associated with prenatal exposure to morphine. 
However, in a study that evaluated first-trimester exposure to oxycodone, no increased risk 
of congenital malformations were reported.39
Cohort Studies—The 33 cohort studies with an unexposed comparison group included in 
our review were published from 1971 through 2015 (Table 3). Similar to the case-control 
studies, many (17 of 33) of the cohort studies were published before 
199918,21,24,25,41,45,47,51,53,56,63,74,76,78,85,86,88 Methadone and heroin were the most 
common opioid exposures evaluated, with methadone maintenance treatment (MMT) as the 
most common indication for methadone exposure. Ten studies did not calculate risk 
estimates of congenital malformations in infants exposed to opioids,13,24,41,45,51,74,80,81,85,85 
and in 5 studies, no congenital malformations were reported in any infant.25,25,57,78,84 Of the 
remaining 18 cohort studies that performed statistical tests to measure 
associations,12,15–,21,47,52,53,56,63,65,66,76,77,87,88 7 reported statistically significant increased 
risks of congenital malformations as a result of prenatal opioid exposure.12,15,19,21,52,55,87 
Four of the 7 studies assessed associations with opioid exposure in aggregate,12,19,21,55 
reporting a statistically significant increased risk of congenital malformations overall in 3 
studies19,21,55 and clubfoot (pes equinovarus) in 1 study.12
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Five of the 7 cohort studies that reported statistically significant increased risks evaluated 
associations between exposure to specific types of opioids and congenital 
malformations.12,15,52,55,87 In 2 studies by Källén et al,12,52 tramadol exposure in early 
pregnancy was associated with a statistically significant increased risk of clubfoot. Källén 
and Reis52 also reported an increased risk of congenital malformations overall, “relatively 
severe malformations” (authors excluded preauricular appendix, tongue tie, patent ductus 
arteriosus in preterm infants, single umbilical artery, undescended testicle, unstable hip or 
hip (sub) luxation, and nevus), heart malformations overall, and isolated cardiac septum 
malformations with tramadol exposure in early pregnancy, as well as congenital 
malformations overall, and “relatively severe malformations” with codeine exposure and an 
increased risk of heart malformations overall with the use of synthetic opioids in early 
pregnancy. The remaining 3 studies evaluated associations with methadone exposure; all 
studies reported an increased risk of malformations overall.15,55,87 Nørgaard et al55 also 
reported an increased risk of malformations associated with prenatal exposure to 
buprenorphine.
Studies With an Exposed Comparison Group
We identified 15 eligible studies with an exposed comparison group, of which 14 were 
cohort studies36, 42, 46, 48, 50, 55, 58–61, 67, 68, 75, 82 and 1 was a cross-sectional study (Table 
1).14 Eleven studies compared methadone exposure to other opioid exposures, including 
methadone detoxification,36 methadone with additional drugs,42 illicit opioids, such as 
heroin,14,46,67,68 MMT with tricyclic antidepressant exposure,48 slow-release oral 
morphine,60 and buprenorphine (Table 4).55,60,61,82 Other studies compared polydrug abuse 
(including opioids) to alcohol abuse alone,50 uncontrolled opioid abuse to methadone 
detoxification,59 opioid maintenance treatment (OMT) alone to OMT with other prescription 
medications,58 and heroin exposure to amphetamine exposure.75 Five studies did not specify 
which exposure groups the congenital malformations were observed in, making their 
findings difficult to interpret.14,42,59,60,67 No congenital malformations were reported in the 
main opioid-exposed groups in 4 other studies.35,48,68,75
Only 3 of the 15 studies with an exposed comparison group performed statistical tests to 
compare findings between exposure groups, with mixed results.45,50,58 Fajemirokun-
Odudeyi et al46 did not report significant differences in the percentage of congenital 
malformations between infants exposed to methadone and those exposed to heroin. Lund et 
al58 reported a significantly higher prevalence of major malformations in children exposed 
to OMT with other prescribed medications compared with those exposed to OMT alone, but 
the documented P value was > .05. Similarly, Iosub et al50 stated that there was a statistically 
significant lower percentage of infants with malformations in the polydrug-exposed group 
(14%) compared with the alcohol-only-exposed infants (33%). However, the documented P 
value was equal to .05.
The remaining 3 studies compared buprenorphine and methadone exposures.55,61,82 Lacroix 
et al55 described similar malformation rates in buprenorphine-exposed and methadone-
exposed infants, and the rates among both prenatally exposed groups were reported to be 
higher than the general French population. Welle-Strand et al82 compared infants prenatally 
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exposed to buprenorphine to those prenatally exposed to methadone and reported 2 cases 
with malformations (spina bifida and gastroschisis) in the buprenorphine group, but no 
malformations in the methadone group. Meyer et al61 also reported 2 cases with 
malformations; 1 infant with an absent hand in the methadone-exposed group and 1 infant 
with isolated cleft palate in the buprenorphine-exposed group.
Descriptive Studies
We included 7 large studies (≥100 participants) that described prenatal opioid exposure and 
congenital malformations, but did not include any comparison group (Table 
5).37,38,44,49,54,62,64 Three of the 7 studies described congenital malformations 
collectively.37,38,44 Blumenthal et al38 reported a higher prevalence of congenital 
malformations in the heroin-exposed group (12.7 per 1000 live births) than among all live 
births in New York City (10 per 1000 live births). Blinick et al37 did not observe any 
congenital malformations among 61 live births prenatally exposed to methadone and/or 
heroin. Davis and Chappel44 reported 4 congenital malformations among the 113 live births 
included in their study, 2 of which were exposed to methadone at conception; however, the 
authors stated that their findings of teratogenic and toxigenic effects of opioids were 
inconclusive.
The remaining 4 studies reported on specific malformations observed with prenatal opioid 
exposure.49,54,62,64 Of the infants prenatally exposed to methadone and/or heroin described 
by Harper et al,49 congenital malformations were observed in 3 (ie, diaphragmatic hernia, 
bifid thoracic vertebrae, and polydactyly). Kivistö et al54 observed malformations in 10 out 
of 102 infants (ie, pulmonary artery stenosis; VSDs; primary vesicoureteral reflux grade III; 
primary vesicoureteral reflux grade III–IV with hydronephrosis; duplex thumb with left-
sided duplex urinary collecting system; palatal cleft with ankyloglossia; Pierre Robin 
syndrome with undescended testicle; microtia with stenotic external ear canal; tetralogy of 
Fallot with bilateral inguinal hernias, multiple skeletal anomalies, and thymic aplasia; and 
mild hypospadias) prenatally exposed to buprenorphine. Of these, 5 infants had a major 
anomaly with functional or cosmetic significance, which was reported to be slightly higher 
than what is observed on average in the general population (3.4%). Miles et al62 reported 2 
cases of cleft palate among infants exposed to methadone during pregnancy (either alone or 
in combination with illicit substances). Lastly, Newman64 reported malformations in 7 
infants exposed to methadone (ie, heart murmurs [not generally considered a congenital 
malformation], hernia, bilateral foot deformity, imperforate anus, and esophageal defect).
Study Quality
We used 2 validated checklists to assess the quality of the 68 studies included in this review 
(Supplemental Figures 3-1, 3-2, 4, and 5).90 We also presented the distribution of the 
included studies with respect to their bias characteristics (Fig 2). Among the 46 studies with 
an unexposed comparison group, 76% were not generalizable, 61% had a high risk of bias 
based on their sampling frame, and 57% did not report response rates. Additionally, less than 
half of the studies assessed outcomes and exposures using gold standards (48% and 28%, 
respectively). However, 61% of the studies evaluated associations after adjusting for 
potential confounders.
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Among the 15 studies with an exposed comparison group, 87% were not generalizable, 80% 
had a high risk of bias based on their sampling frame, and 73% did not report response rates. 
Approximately half of these studies used gold standard assessments for the outcome and 
addressed confounding. However, because many of these studies used data collected from 
opioid treatment facilities, a much larger proportion (67%) of studies used gold standard 
measurements for exposure assessment than studies with an unexposed comparison group. 
Among the 7 descriptive studies, none were generalizable, all had a high risk of bias based 
on their sampling frame, and none reported response rates. Although only 43% of the 
descriptive studies had a low risk of bias in outcome assessment, 71% used gold standards to 
assess exposures.
DISCUSSION
We included 68 studies in this systematic review, of which 30 (12 case-control and 18 cohort 
studies with an unexposed comparison group) performed statistical tests to measure 
associations between opioid exposure during pregnancy and congenital malformations. Of 
those 30 studies, 17 demonstrated statistically significant positive associations between 
prenatal opioid exposure and at least 1 congenital malformation (Supplemental Table 6); 10 
were case-control studies and 7 were cohort studies. Among the 10 case-control studies, oral 
clefts and VSDs/atrial septal defects were the most frequently reported specific 
malformations (reported in 3 studies each; Supplemental Table 7), followed by spina bifida, 
which was reported in 2 studies. Four of these studies also reported statistically significant 
positive associations with codeine exposure, where heart malformations were the most 
frequently reported (3 of 4) congenital malformations mentioned. Among the 7 cohort 
studies, 6 reported increased risks of congenital malformations overall with prenatal opioid 
exposure, and the most frequently reported specific malformation was clubfoot (reported in 
2 studies).
We have considerable concerns regarding the quality of the studies included in this review. 
There were no randomized controlled trials and few high-quality observational studies that 
evaluated the association between prenatal opioid use and congenital malformations. 
However, we acknowledge that this is a limitation of most medication-related studies in the 
pregnancy literature. The majority of the included studies lacked generalizability, failed to 
report response rates, and were older publications (published before 1999), which is a 
concern given the dramatic increases in opioid use since 1999.91 Although most of the case-
control studies with an unexposed comparison group used appropriate sampling frames and 
methods, almost all of the other studies had flaws in their sampling frame. Many of the 
studies also had limitations with outcome and/or exposure measurement, which might have 
resulted in misclassification. Although the studies with an unexposed comparison group 
would be considered the highest quality of those included in this review, potential 
information biases were identified in half of them, and confounding was not properly 
addressed in many. Additionally, over half of the 68 studies included in this review were 
cohort studies. In general, population-based cohort studies are not ideal for assessing rare 
outcomes because most have insufficient power to assess specific congenital malformations. 
Thus, many of the included studies assessed congenital malformations as 1 homogenous, 
aggregate group. However, congenital malformations are etiologically heterogeneous, and 
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examining all congenital malformations combined is unlikely to identify potentially 
teratogenic effects.92 This underpowering of cohort studies for rare outcomes likely explains 
why a much higher proportion of the case-control studies (10 of 12) documented statistically 
significant positive associations between prenatal opioid use and congenital malformations 
when compared with the cohort studies (7 of 18) included in this review. Furthermore, the 
majority of the studies included in this review had relatively small numbers of participants, 
which additionally limits their ability to assess the risk for congenital malformations due to 
insufficient power.
Limitations and Strengths
It is important to acknowledge some additional limitations of this review. Restricting our 
literature search to the English language may have led to a lack of heterogeneity among the 
reported settings and populations. Additionally, restricting to full-text journal articles may 
have introduced publication bias by excluding any reports of negative findings that did not 
become full-text publications. Moreover, in instances of substance use, it is rare for only 1 
substance to be misused or abused, making it difficult to evaluate and understand the effects 
of individual substances on birth outcomes.10 This challenge is compounded by the often 
absent or insufficient prenatal care observed in pregnant women with OUD, significantly 
higher rates of tobacco use among pregnant women with substance use disorders,93 and 
lifestyle issues associated with illicit drug use that expose pregnant women to sexually 
transmitted infections and other risks,94 all of which increase the risk for poor birth 
outcomes,94,95 additionally limiting our ability to draw conclusions from study findings. 
Finally, due to exposure measurement limitations and the overall poor quality of many of the 
studies included in this systematic review, we were unable to incorporate information on 
exposure intensity/dose or additionally group the studies by reasons for exposure (eg, illicit, 
maintenance treatment, or prescribed). Because several factors play a role in substance use 
among women, including ethnicity, culture, sexual orientation, and socioeconomic status, it 
is likely that the study populations varied based on the reasons for prenatal opioid 
exposure10; yet, many of the studies we included failed to properly address confounding, 
which additionally prevents the generalizing of study findings.
Our review has a number of strengths. We attempted to address the potential for retrieval 
bias that is inherent in most reviews by using well-defined search terms in multiple 
electronic databases and by hand-searching the reference lists of eligible studies. Another 
strength was our use of a systematic, standardized, duplicate review process to identify 
eligible studies and ensure a relatively thorough retrieval of published literature on opioid 
use during pregnancy and congenital malformations. Finally, we used validated checklists to 
assess study quality, which allowed for more objective assessments.
CONCLUSIONS
Our findings in this systematic review have implications for future research and clinical 
practice. Well-designed studies with unexposed comparison groups that estimate measures 
of association are needed. Ideally, these studies should also have enough power to assess 
associations between specific opioids used during pregnancy and specific congenital 
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malformations, rather than malformations and/or opioids as aggregate groups, and to 
adequately control for potential confounding factors, including polysubstance use and 
tobacco use. Given the uncertainty that remains regarding the teratogenicity of opioids, a 
careful evaluation of the potential risks and benefits is warranted when making clinical 
decisions regarding the use of opioid therapy in reproductive-aged and pregnant women. 
According to the recent Centers for Disease Control and Prevention Guideline for 
Prescribing Opioids for Chronic Pain, when opioids are being considered for reproductive-
aged women to manage chronic pain, health care providers are encouraged to discuss (1) 
family planning and (2) how long-term opioid use might affect any future pregnancy.96 For 
health care providers caring for pregnant women taking opioid medications, the guidelines 
recommend that they (1) access appropriate expertise if considering tapering opioids, (2) 
offer medication-assisted therapy with buprenorphine or methadone to pregnant women with 
OUD, and (3) arrange for delivery at a facility prepared to monitor, evaluate for, and treat 
NAS.
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FIGURE 1. 
Flowchart for inclusion of studies in a systematic review of prenatal opioid exposure and 
congenital malformations.
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FIGURE 2. 
Risk of bias across studies included in a systematic review of prenatal opioid exposure and 
congenital malformations. (A) Studies with an unexposed comparison group (n = 46). (B) 
Studies with an exposed comparison group (n = 15). (C) Descriptive studies (n = 7).
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TABLE 2
Case-Control Studies With an Unexposed Comparison Group That Investigated Associations Between 
Prenatal Opioid Exposure and Congenital Malformations (n = 13)
Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Bracken and 
Holford39 
(1981)
Narcotic analgesics; codeine; 
thebaine (oxycodone)
Any and specific major congenital 
malformations
First exposure to narcotic analgesics in first 
trimester
 Major congenital malformations: OR, 3.6; 
95% CI, 1.8–7.2
 Specific malformations (P < .01): cleft lip/
palate; VSD + ASD; and other heart and 
circulatory defects
 Specific malformations (P < .05): dislocated 
hip/musculoskeletal defects; inguinal hernia 
with/without obstruction
 Specific malformations (P > .05): alimentary 
tract; CNS anomalies/spina bifida; heart valve 
defect; polydactyly/syndactyly; down 
syndrome; hemangioma; pyloric stenosis; 
skanomalies; talipes; TGV; and other 
congenital malformations
First exposure to specific opioids in first 
trimester
 Codeine: P = .004
 Thebaine (oxycodone): P = .07
Reasons: medical (prescribed) First exposure to narcotic analgesics in second 
trimester
 Major congenital malformations: P > .05
 Specific malformations (P < .05): alimentary 
tract
 Specific malformations (P > .05): CNS 
anomalies/spina bifida; cleft lip/palate; 
dislocated hip/musculoskeletal defects; down 
syndrome; heart valve defect; hemangioma; 
inguinal hernia with/without obstruction; 
polydactyly/syndactyly, pyloric stenosis; 
skanomalies; talipes, TGV; VSD + ASD; other 
heart and circulatory defects; and other 
congenital malformations
First exposure to narcotic analgesics in third 
trimester
Major congenital malformations: P > .05
Brack40 (1986) Codeine Reasons: medical 
(prescribed)
CHDs Controls (without any congenital 
malformations): PR, 2.4; 95% CI, 1.1–5.2
Controls (including infants with other 
malformations): PR, 1.3; 95% CI, 0.7–3.9
Broussard et 
al34 (2011)
Opioid analgesic treatment (ie, 
codeine; hydrocodone; 
meperidine; oxycodone; 
propoxyphene; morphine; 
tramadol; methadone; 
hydromorphone; fentanyl; 
pentazocine)
Specific major congenital 
malformations
Non-heart defects
 Anencephaly/craniorachischisis: aOR 1.7; 
95% CI 0.84–3.4
 Spina bifida: aOR, 2.0; 95% CI, 1.3–3.2
 Cleft palate: aOR, 1.3; 95% CI, 0.84–2.0
 Cleft lip with cleft palate: aOR, 1.4; 95% CI, 
0.96–2.1
 Cleft lip without cleft palate: aOR, 0.68; 
95% CI, 0.34–1.3
CHDs
 Any of included CHDs: aOR, 1.4; 95% CI, 
1.1–1.7
 Anomalous pulmonary venous return: aOR, 
0.71; 95% CI, 0.22–2.3
 Aortic stenosis: aOR, 1.3; 95% CI, 0.61–2.9
 ASD secundum: aOR, 1.3; 95% CI, 0.94–1.9
 ASD not otherwise specified: aOR, 2.0; 95% 
CI, 1.2–3.6
 AVSD: aOR, 2.4; 95% CI, 1.2–4.8
 Coarctation of aorta: aOR, 0.88; 95% CI, 
0.47–1.6
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Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Reasons: medical (not 
maintenance treatment)
 Conotruncal defects: aOR 1.5; 95% CI, 1.0–
2.1
 d-TGA: aOR, 1.1; 95% CI, 0.56–2.1
 HLHS: aOR, 2.4; 95% CI, 1.4–4.1
 Laterality defects with CHD: aOR, 1.2; 95% 
CI, 0.42–3.2
 Left ventricular outflow tract obstruction 
defects: aOR, 1.5; 95% CI, 1.0–2.2
 PVS: aOR, 1.7; 95% CI, 1.2–2.6
 Right ventricular outflow tract obstruction 
defects: aOR, 1.6; 95% CI, 1.1–2.3
 Septal defects: aOR, 1.2; 95% CI, 0.93–1.6
 Single ventricle/complex: aOR, 1.1; 95% CI, 
0.42–3.2
 Tetralogy of Fallot: aOR, 1.7; 95% CI, 1.1–
2.8
 VSD conoventricular: aOR, 2.7; 95% CI, 
1.1–6.3
 VSD perimembranous: aOR, 0.99; 95% CI, 
0.65–1.5
 VSD + ASD: aOR, 1.7; 95% CI, 1.0–2.9
 VSD + PVS: aOR, 1.3; 95% CI, 0.46–3.7
Daud et al43 
(2015)
Morphine Reasons: medical 
(prescribed)
Specific congenital malformations 
(ie, CHDs; musculosk; digestive; 
urinary; oral clefts; genital; CNS; 
limb; eye, ear, face, neck; 
respiratory)
Respiratory: OR, 100.9; 95% CI, 10.39–979.94
Rothman et al69 
(1979)
Codeine Reasons: not specified CHDs CHDs: PR, 4.1; 90% CI, 1.3–13
Saxén70 (1975) Opioids Reasons: not specified Oral clefts Matched-pair analysis: RR, 3.42a
Random-sample study: RR, 3.40a
Yule’s Q coefficient analysis (describes the 
degree of association between two 2-category 
variables)
 Oral clefts crude association: P < .025
Saxén71 (1975) Opioids (mainly codeine) 
Reasons: not specified
Specific congenital malformations Exposure in first trimester
Entire study group: P < .001
 Specific malformations (P < .01): cleft 
palate with no additional defects; cleft lip with 
or without cleft palate with no additional 
defects
 Specific malformations (P > .05): cases with 
additional defects
Exposure in second trimester
 Entire study group: P > .05
 Specific malformations (P > .05): cleft 
palate with no additional defects; cleft lip with 
or without cleft palate with no additional 
defects; cases with additional defects
Exposure in third trimester
 Entire study group: P > .05
 Specific malformations (P > .05): cleft 
palate with no additional defects; cleft lip with 
or without cleft palate with no additional 
defects; cases with additional defects
Shaw et al72 
(1992)
Codeine Reasons: not specified CHDs CHDs: OR, 0.70; 95% CI, 0.20–2.4
Shaw et al73 
(1998)
Codeine Reasons: not specified NTDs NTDs: OR, 0.89; 95% CI, 0.35–2.24
van Gelder et 
al79 (2009)
Opioids (ie, diacetylmorphine/
heroin; oxycodone 
hydrochloride; hydrocodone 
bitartrate; methadone) Reasons: 
illicit; medical (not maintenance 
treatment)
Specific congenital malformations 
(ie, NTDs; several CHDs; oral 
clefts; certain gastrointestinal 
defects)
Too few infants exposed to estimate risks of 
congenital malformations
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Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Werler et al83 
(2014)
Opioids (ie,hydrocodone; 
codeine; oxycodone; morphine; 
methadone; buprenorphine; 
fentanyl; proxyphene; 
meperidine) Reasons: not 
specified
Isolated clubfoot Any length of opioid exposure
 Isolated cases: aOR, 1.56; 95% CI, 0.92–
2.66
 Isolated cases among those with first degree 
clubfoot relatives: aOR, 1.77; 95% CI, 1.03–
3.03
≤ 14 d of opioid exposure: aOR, 1.44; 95% CI, 
0.67–3.12
>14 d of opioid exposure: aOR, 1.65; 95% CI, 
0.81–−3.35
Yazdy et al35 
(2013)
Opioids (ie, codeine; oxycodone; 
hydrocodone; morphine; 
propoxyphene; meperidine; 
methadone; tramadol; 
hydromorphone; butorphanol; 
heroin; fentanyl; buprenorphine; 
nalbuphine; diphenoxylate); 
codeine-containing products; 
non–codeine- containing 
products
Reasons: illicit; medical (not 
maintenance treatment)
NTDs (ie, anencephaly; 
encephalocele; spina bifida); spina 
bifida separately
Controls (without congenital malformations)
 Any opioids: all NTDs: aOR, 2.2; 95% CI, 
1.2–4.2
 Any opioids: spina bifida: aOR, 2.5; 95% 
CI, 1.3–5.0
 Codeine-all NTDs: aOR, 2.5; 95% CI, 1.0–
6.3
 Codeine: spina bifida: aOR, 2.5; 95% CI, 
0.9–7.4
 Noncodeine: all NTDs: aOR, 2.2; 95% CI, 
1.0–4.9
 Noncodeine: spina bifida: aOR, 2.8; 95% CI, 
1.3–6.3
Controls (with congenital malformations)
 Any opioids: all NTDs: aOR, 1.9; 95% CI, 
1.0–3.4
 Any opioids: spina bifida: aOR, 2.2; 95% 
CI, 1.1–4.1
 Codeine: all NTDs: aOR, 2.0; 95% CI, 0.9–
4.7
 Codeine: spina bifida: aOR, 2.0; 95% CI, 
0.7–5.5
 Noncodeine: all NTDs: aOR, 1.9; 95% CI, 
0.9–4.1
 Noncodeine: spina bifida: aOR, 2.5; 95% CI, 
1.1–5.4
Zierler and 
Rothman89 
(1985)
Codeine Any and specific CHDs Controls (no congenital malformations)
 Any CHD: cPOR, 2.0; 90% CI 1.1–3.6
Controls (population)
 Any CHD (exposure from maternal report): 
cPOR, 1.9; 90% CI, 0.78–4.4
 Any CHD (exposure from obstetric record): 
cPOR, 2.4; 90% CI, 0.55–10.3
 VSD: cPOR, 2.5; 90% CI 1.2–5.2
Reasons: not specified  DORV: cPOR, 5.7; 90% CI 1.2–19.7
Controls (other CHDs)
 VSD: cPOR, 1.5; 90% CI, 0.60–3.9
 DORV: cPOR, 3.2; 90% CI, 0.66–11.6
Controls (other congenital malformations)
 DORV: aPOR, 5.0; 90% CI, 1.2–21.7
aOR: Adjusted odds ratio; aPOR: Adjusted prevalence odds ratio; ASD: Atrial septal defect; AVSD: Atrioventricular septal defect; CHD: 
Congenital heart defect; CI: Confidence interval; CNS: Central nervous system; cPOR: Crude prevalence odds ratio; DORV: Double-outlet right 
ventricle; d-TGA: dextro-transposition of the great arteries; HLHS: Hypoplastic left heart syndrome; NTD: Neural tube defect; OR: Odds ratio; PR: 
Prevalence ratio; PVS: Pulmonary valve stenosis; RR: Riskratio; TGV: Transposition of the great vessels.
a
Confidence limits and/or P values not specified.
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TABLE 3
Cohort Studies With an Unexposed Comparison Group That Investigated Associations Between Prenatal 
Opioid Exposure and Congenital Malformations (n = 33)
Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Brown et al24 
(1998)
Methadone; other opioids
Reasons: illicit; maintenance 
treatment
Major congenital malformations Methadone group: 9.3% prevalence of 
congenital malformations
Unexposed group: none of the infants had 
a congenital malformation
Chasnoff et al41 
(1982)
Polydrug abuse (no methadone); 
heroin to methadone
Reasons: illicit; maintenance 
treatment
Specific congenital malformations Polydrug-abuse group: 2 infants with 
hand deformities (exposed to pentazocine 
and pyribenzamine)
Heroin to methadone group: 5 infants 
with inguinal hernia (2 also had second-
degree hypospadias)
Cleary et al15 
(2011)
Methadone
Reasons: maintenance treatment
Congenital malformations (major; 
minor; chromosomal)
Any congenital malformation: aOR, 2.20; 
95% CI, 1.54–3.14
Major congenital malformation: aOR, 
1.94; 95% CI, 1.10–3.43
Minor congenital malformation: aOR, 
2.12; 95% CI, 1.26–3.56
Chromosomal malformation: aOR, 1.48; 
95% CI, 0.19–11.4
Unclassified congenital malformation: 
aOR, 7.26; 95% CI, 2.58–20.4
Ellwood et al45 
(1987)
Heroin; methadone Reasons: illicit; 
maintenance treatment
Any and specific congenital 
malformations
Exposed group: 1 infant with 
anencephaly
Unexposed group: 1 infant with severe 
spina bifida
Saleh Gargari et 
al16 (2012)
Opium; heroin; methadone
Reasons: illicit
Any and specific congenital 
malformations (ie, clubfoot; 
micropenis; macrocephaly; cardiac 
anomaly; anomalies of limbs; 
hypospadias; polydactyly)
Opioid-exposed group: there was no 
statistically significant difference in 
congenital malformations between 
exposed and unexposed groups
All drugs (not limited to opioids) group: 
RR, 2.66; 95% CI, 1.16–6.05
Gillogley et al47 
(1990)
Opioids Reasons: illicit Any congenital malformations Opiates-only group: none of the infants 
had a congenital malformation
Multichemical (cocaine, amphetamine, 
and/or opiates) group: 2.9% prevalence of 
congenital malformations but there was 
no statistically significant difference in 
congenital malformations between 
exposed and unexposed groups
Greig et al17 
(2012)
Heroin; methadone
Reasons: illicit; maintenance 
treatment
Any congenital malformations There was no statistically significant 
difference in congenital malformations 
between exposed and unexposed groups
Jick et al51 (1981) Codeine; propoxyphene N; 
meperidine; propoxyphene 
hydrochloride and acetaminophen 
(Darvocet N) Reasons: medical 
(prescribed)
Any and specific congenital 
malformations
Terpin hydrate and codeine group: 1 
infant with congenital malformations
Propoxyphene N group: 1 infant with 
congenital malformations
Meperidine group: 1 infant with 
congenital malformations Aspirin + 
phenacetin + caffeine + codeine 
phosphate (APC with codeine) group: 3 
infants with congenital malformations
Kahila et al26 
(2007)
Buprenorphine
Reasons: maintenance treatment
Any congenital malformations Buprenorphine group: none of the infants 
had a congenital malformation
Controls (population): no mention of 
prevalence of congenital malformations
Källén12 (2013) Opioids (ie, morphine; morphine + 
spasmolytics; hydromorphone; 
hydromorphone + spasmaolytics; 
oxycodone; codeine + paracetamol; 
ketobemidone; ketobemidone + 
Any and specific congenital 
malformations
Any opioids in early pregnancy Any 
congenital malformations: OR, 1.02; 95% 
CI, 0.92–1.12
Chromosomal malformations: OR, 0.83; 
95% CI, 0.50–1.37
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Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
spasmolytica; pethidine; fentanyl; 
methadone; dextropropoxyphene; 
dextropropoxyphene + paracetamol/
aspirin; pentazocine; buprenorphine; 
tramadol; unspecified opioid; 
naltrexone; buprenorphine; 
methadone; buprenorphine 
combination)
Reasons: not specified
Relatively severe congenital 
malformations: OR, 1.03; 95% CI, 0.91–
1.15 NTDs: RR, 1.22; 95% CI, 0.36–2.60
Other CNS malformations: RR, 1.40; 
95% CI, 0.60–2.76
Orofacial clefts: OR, 0.49; 95% CI, 0.25–
0.96 Any cardiovascular malformations: 
OR, 1.04; 95% CI, 0.85–1.27
Septal cardiac defect: OR, 1.04; 95% CI, 
0.82–1.32
Pyloric stenosis: RR, 0.92; 95% CI, 0.34–
2.01
Abdominal wall defect: RR, 1.44; 95% 
CI, 0.30–4.19
Diaphragmatic hernia: RR, 1.36; 95% CI, 
0.28–3.99
Hypospadias: OR, 0.97; 95% CI, 0.65–
1.44
Major renal malformations: RR, 0.58; 
95% CI, 0.12–1.71
Pes equinovarus: OR, 1.68; 95% CI, 
1.10–2.55
Poly- or syndactyly: OR, 0.95; 95% CI, 
0.58–1.56
Limb reduction defects: RR, 1.73; 95% 
CI, 0.75–3.41
Craniostenosis: RR, 0.60; 95% CI, 0.12–
1.76 Codeine + paracetamol in early 
pregnancy: there was no statistically 
significant difference in congenital 
malformations
Dextropropoxyphene in early pregnancy: 
there was no statistically significant 
difference in congenital malformations
Tramadol in early pregnancy
 Any tramadol: pes equinovarus: RR, 
3.60; 95% CI, 1.72–6.62
 Excluding anticonvulsant: pes 
equinovarus: RR, 3.88; 95% CI, 1.86–
7.13
 Excluding women with previous 
miscarriages and/or born outside
  Sweden: pes equinovarus: RR, 4.17; 
95% CI, 1.35–9.72
Any opioids + anticonvulsants in early 
pregnancy
 Relatively severe malformations: RR, 
1.37; 95% CI, 0.44–3.19
Any opioids + sedative/hypnotics in early 
pregnancy
 Relatively severe malformations: OR, 
0.75; 95% CI, 0.44–1.29
 Any cardiovascular malformations: 
RR, 0.49; 95% CI, 0.10–1.44
Any opioids + antidepressants in early 
pregnancy
 Relatively severe malformations: RR, 
1.09; 95% CI, 0.71–1.68
 Any cardiovascular malformations: 
RR, 1.23; 95% CI, 0.53–2.43
Källén and Reis52 
(2015)
Opioids (ie, tramadol; other opioids 
not used for MMT; codeine + 
paracetamol/aspirin; other natural 
opiates (not codeine); 
dextropropoxyphene ± paracetamol/
aspirin; other synthetic opioids (not 
tramadol/dextropropoxyphene)
Reasons: medical (prescribed)
Any and specific congenital 
malformations
Tramadol in early pregnancy
 Any malformations: aOR, 1.30; 95% 
CI, 1.06–1.69
 Relatively severe malformations: aOR, 
1.33; 95% CI, 1.05–1.70
 Any cardiovascular malformations: 
aOR, 1.56; 95% CI, 1.04–2.29
 Isolated cardiac septum malformation: 
aRR, 1.78; 95% CI, 1.02–2.90
 Pes equinovarus: aRR, 3.63; 95% CI, 
1.61–6.89
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Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
 Hypospadias: aRR, 0.95; 95% CI, 
0.31–2.21
 Polydactyly: aRR, 1.77; 95% CI, 0.48–
4.33
Codeine in early pregnancy
 Any malformations: aOR, 1.42; 95% 
CI, 1.19–1.69
 Relatively severe malformations: aOR, 
1.42; 95% CI, 1.15–1.76
 Any cardiovascular malformations: 
aOR, 1.38; 95% CI, 0.97–1.96
 Isolated cardiac septum malformation: 
aOR, 1.31; 95% CI, 0.80–2.14
 Pes equinovarus: aRR, 1.24; 95% CI, 
0.34–3.18
Other natural opiates in early pregnancy
 Any malformations: aOR, 1.20; 95% 
CI, 0.80–1.81
 Relatively severe malformations: aOR, 
1.17; 95% CI, 0.71–1.93
 Any cardiovascular malformations: 
aRR, 0.86; 95% CI, 0.23–2.19
Dextropropoxyphene in early pregnancy
 Any malformations: aOR, 1.07; 95% 
CI, 0.91–1.26
 Relatively severe malformations: aOR, 
1.06; 95% CI, 0.87–1.28
 Any cardiovascular malformations: 
aOR, 0.97; 95% CI, 0.68–1.32
 Isolated cardiac septum malformation: 
aOR, 1.01; 95% CI, 0.62–1.66
 Pes equinovarus: aRR, 1.68; 95% CI, 
0.72–3.30
Other synthetic opioids in early 
pregnancy
 Any malformations: aOR, 1.25; 95% 
CI, 0.75–2.08
 Relatively severe malformations: aOR, 
1.30; 95% CI, 0.71–2.38
 Any cardiovascular malformations: 
aRR, 2.94; 95% CI, 1.18–6.06
 Isolated cardiac septum malformation: 
aRR, 1.59; 95% CI, 0.52–3.72
Kandall et al53 
(1977)
Heroin; methadone; heroin + 
methadone
Reasons: illicit; maintenance 
treatment
Any and specific congenital 
malformations
Heroin group: 1 infant with stigmata of 
Down syndrome and 1 infant with 
isolated microcephaly
Methadone group: 1 infant with stigmata 
of Down syndrome
Heroin + methadone group: 1 infant with 
isolated microcephaly
Past history of drug abuse (but drug-free 
during current pregnancy) group: 1 infant 
with isolated microcephaly
Frequencies of “recognizable” 
malformations across groups were not 
statistically significantly different
Lam et al56 (1992) Heroin; methadone
Reasons: illicit; maintenance 
treatment
Any congenital malformations There was no statistically significant 
difference in congenital malformations 
between exposed and unexposed groups
Lendoiro et al57 
(2013)
Opioids; methadone; fentanyl
Reasons: illicit; medical (prescribed)
Any congenital malformations None of the infants in either the exposed 
or the unexposed groups had a congenital 
malformation
Little et al18 
(1990)
Heroin; methadone
Reasons: illicit
Any, major, and specific congenital 
malformations (ie, hip dislocation; 
natal teeth; polydactyly; skin tag; 
supernumerary nipple; umbilical 
hernia; undescended testes; vaginal 
tag)
There was no statistically significant 
difference in congenital malformations 
between exposed and unexposed groups
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Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Ludlow et al13 
(2004)
Heroin alone or with other drugs; 
heroin with methadone; methadone 
only
Reasons: illicit; maintenance 
treatment
Specific congenital malformations 
(ie, talipes; cleft palate and low set 
ears; coarctation of the aorta, 
laevocardia, and cerebral anomalies; 
renal anomaly)
Opioid-exposed group: 3 infants with 
talipes and 1 infant with cleft palate and 
low-set ears
Naeye et al63 
(1973)
Heroin; methadone
Reasons: illicit; maintenance 
treatment
Specific congenital malformations 
(ie, cardiac malformations; 
tracheoesophageal fistula; 
diaphragmatic hernia; clubfeet)
Any opioid exposure: there was no 
statistically significant difference in 
congenital malformations between 
exposed and unexposed groups in infants 
who were stillborn/died within the first 
72 h after birth
Heroin until delivery group: 4% of 
infants with cardiac malformations, 4% 
with tracheoesophageal fistula, and 4% 
with clubfeet
Methadone until delivery group: none of 
the infants had a congenital malformation
Heroin during early pregnancy only 
group: 10% of infants with diaphragmatic 
hernia
Non-drug-addicted group: 8% of infants 
with cardiac malformations, 1% with 
tracheoesophageal fistula, 1% with 
diaphragmatic hernia, and 1% with 
clubfeet
Non-drug-addicted + hepatitis group: 
14% of infants had cardiac 
malformations
Nezvalova- 
Henriksen et al65 
(201 1)
Codeine (alone or in fixed 
combination with paracetamol)
Any and major congenital 
malformations
Any exposure in pregnancy
 Any congenital malformations: aOR, 
0.9; 95% CI, 0.8–1.1
 Major congenital malformations: aOR, 
0.9; 95% CI, 0.7–1.2
Exposure in first trimester
 Any congenital malformations: aOR, 
0.9; 95% CI, 0.7–1.1
 Major congenital malformations: aOR, 
0.8; 95% CI, 0.5–1.1
Reasons: not specified Exposure in second trimester
 Any congenital malformations: aOR, 
0.9; 95% CI, 0.7–1.1
 Major congenital malformations: aOR, 
0.8; 95% CI, 0.6–1.1
Exposure in third trimester
 Any congenital malformations: aOR, 
1.0; 95% CI, 0.7–1.3
 Major congenital malformations: aOR, 
1.1; 95% CI, 0.8–1.6
Nørgaard et al66 
(2015)
Any opioids; methadone only; 
buprenorphine only; heroin only; 
combinations
Reasons: illicit; maintenance 
treatment; medical (prescribed)
Any congenital malformations Any opioids group: PR, 2.0; 95% CI, 
1.5–2.6
Buprenorphine group: PR, 2.0; 95% CI, 
1.2–3.2
Methadone group: PR, 2.4; 95% CI, 1.6 
-3.7
Heroin group: PR, 0.9; 95% CI, 0.1–57
Combination group: PR, 1.6; 95% CI, 
0.9–2.8
Ostrea and 
Chavez21 (1979)
Heroin; heroin and methadone 
Reasons: illicit
Any and specific congenital 
malformations
Opioid-exposed group
 17 infants with minor congenital 
malformations
 20 infants with significant congenital 
malformations (2 with hydrocephalus, 2 
with interrupted aortic arch, 4 with patent 
ductus arteriosus, 1 with VSD, 1 with 
malrotation of the intestines, 2 with 
posterior urethral valves, 1 with 
multicystic kidney, 3 with hypospadias, 1 
with hypoplastic lung, 1 with cleft lip, 
and 2 with inguinal hernias)
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Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Controls (unexposed)
 Significant congenital malformations: 
P < .01
Controls (population)
 Significant congenital malformations: 
P < .01
Rosen and 
Johnson25 (1982)
Heroin; methadone; opioids
Reasons: illicit; maintenance 
treatment
Any congenital malformations None of the infants had a congenital 
malformation
Stimmel and 
Adamsons74 
(1976)
Heroin; methadone
Reasons: illicit; maintenance 
treatment
Specific congenital malformations Opioid exposed group: 1 infant with 
microcephaly, 1 infant with polydactyly, 
and 1 infants with hydrocele
Thornton et al76 
(1990)
Heroin; methadone
Reasons: illicit; maintenance 
treatment
Any and specific congenital 
malformations
Opioid exposed group
 1 infant with gastrointestinal atresia 
and 1 infant with dislocatable hip in a 
twin breech
 Incidence: 4.8%; 95% CI, 
0.58%-16.16%
Controls (unexposed)
 1 infant with CHD
 Incidence: 2.63%; 95% CI, 
0.07%-13.81%
Controls (population)
 Incidence: 2.8%
Uebel et al77 
(2015)
Opioids (assumed based on 
diagnosis of NAS)
Reasons: not specified
Any congenital malformations NAS-diagnosed group: 3 infants admitted 
to hospital for congenital malformations
No-NAS group: 1359 admitted to 
hospital for congenital malformations
NAS versus no-NAS comparison: P = .35
van Baar et al78 
(1989)
Methadone with or without heroin 
and other drugs
Reasons: illicit; maintenance 
treatment
Any congenital malformations None of the infants had a congenital 
malformation
Vucinovic et al19 
(2008)
Heroin and/or methadone with or 
without other drugs
Reasons: illicit
Any and specific congenital 
malformations
Opioid-exposed group
 Any congenital malformation: RR 4; 
95% CI, 1.9–9.2
 Specific congenital malformations: 5 
infants with CHDs (3 with VSD, 1 with 
TGV, and 1 with HLHS), 1 with small 
intestine malrotation, 1 with polydactyly, 
and 1 with single umbilical artery
Walhovd et al80 
(2007)
Heroin with or without other 
substance abuse
Reasons: illicit
Myelomeningocele Heroin-exposed group: 1 infant with 
myelomeningocele
Walhovd et al81 
(2010)
Opioids; heroin
Reasons: illicit
Myelomeningocele Opioid-exposed group: 1 infant with 
myelomeningocele
White et al84 
(2006)
Heroin with dihydrocodeine; 
methadone
Reasons: illicit; maintenance 
treatment
Any and specific congenital 
malformations
None of the infants had a congenital 
malformation
Wilson et al85 
(1981)
Heroin; methadone
Reasons: illicit; maintenance 
treatment
Specific congenital malformations 
(ie, hydrocephalus; flexion 
contractures; cystic fibrosis)
Heroin-exposed group: 1 infant with 
hydrocephalus
Methadone-exposed group: 1 infant with 
flexion contractures
Unexposed group: 1 infant with cystic 
fibrosis
Wilson86 (19 89) Heroin; methadone
Reasons: illicit; maintenance 
treatment
Any and specific congenital 
malformations
Heroin-exposed group: 1 infant with 
spastic diplegia and 1 infant with 
hydrocephalus
Wouldes and 
Woodward87 
(2010)
Methadone
Reasons: maintenance treatment
Any and specific congenital 
malformations
High-dose methadone group: 1 infant 
with periventricular leukomalacia, 1 
infant with CHD and left vocal palsy, and 
1 infant with cleft palate
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Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
None versus low-dose versus high-dose 
methadone comparison: P = .003
Zelson et al88 
(1971)
Heroin Major congenital malformations Heroin-exposed group: 1 infant with 
congenital heart lesion, 1 infant with 
multiple anomalies including a 
tracheoesophageal fistula, 1 infant with 
arthrogryposis multiplex, 1 infant with 
incontinenti pigmenti, and 7 infants 
developed inguinal hernias in the 
immediate newborn period
Reasons: illicit Unexposed population (hospital): 
congenital malformations not reported
Congenital malformations did not occur 
with any more frequency as a result of 
ingestion of heroin and the many other 
drugs taken than in the general 
population
aOR, adjusted odds ratio; CHD, congenital heart defect; CI, confidence interval; CNS, central nervous system; HLHS, hypoplastic left heart 
syndrome; NTD, neural tube defect; OR, odds ratio; RR, risk ratio; TGV, transposition of the great vessels.
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TABLE 4
Studies With an Exposed Comparison Group That Investigated Associations Between Different Prenatal 
Opioid-Related Exposures and Congenital Malformations (n = 15)
Source Main Comparison 
Groups/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Blinick36 (1971) Methadone detoxification 
versus MMT
Reasons: detoxification; 
maintenance treatment
Any congenital malformation Methadone detoxification group: 2 infants 
born with congenital malformations
MMT group: none of the infants had a 
congenital malformation
Cleary et al42 (2012) Methadone only versus 
methadone + additional 
drugs
Reasons: maintenance 
treatment; illicit
Any and specific congenital 
malformations
Congenital malformations (exposure group 
not specified): 1 each of trigonocephaly, VSD, 
and congenital melanocytic naevus
Fajemirokun-
Odudeyi et al46 (2 0 0 
6)
Methadone versus heroin
Reasons: maintenance 
treatment; illicit
Any congenital malformation χ2 comparison of congenital malformations 
between groups: not significant
Green et al48 (1988) MMT + TCA exposure 
versus MMT (no TCA 
exposure)
Reasons: maintenance 
treatment; illicit (other 
opioids)
Specific congenital malformations (ie, 
palate deformity)
MMT + TCA exposed group: 1 palate 
deformity
losub et al50 (1985) Alcohol abuser only versus 
polydrug abusers (alcohol 
and narcotics) Reasons: 
illicit
Major congenital malformations Prevalence of major congenital 
malformations: alcohol-only group (group I) = 
33% compared with polydrug-abuse group 
(group II) = 14% (P = .05; authors considered 
this to be statistically significant)
Prevalence of major congenital malformations 
(excluding severe microcephaly): group I = 
31.5% compared with group II = 14%
Lacroix et al55 (2011) Buprenorphine versus 
methadone
Reasons: maintenance 
treatment
Any and specific congenital 
malformations
Malformation rates: similar in the 2 groups of 
pregnant women (note: higher than the 
general French population)
Buprenorphine group: 1 each of tragus 
appendix; nasal septum deviation plus short 
neck; laproschisis; facial abnormalities plus 
microcephaly; and a therapeutic abortion due 
to malformation of legs, arms, and 
genitourinary system
Methadone group: 1 polymalformation with 
facial malformations plus short thorax, short 
legs, and arms plus syndactyly plus 
micropenis plus multicystic kidneys; and 1 
stillbirth due to achondroplasia
Lund et al58 (2013) OMT without other 
prescribed medications 
versus OMT with other 
prescribed medications
Reasons: maintenance 
treatment
Major congenital malformations (ie, 
hydrocephalus, VSD, clubfoot, 
hypospadias torticollis, muscle 
macrocephaly, gastroschisis, trisomy 
21, pulmonary infundibular stenosis)
Prevalence of major malformations: 
significantly higher in children whose mothers 
were comedicated with opioids, 
benzodiazepines, or z-hypnotics (P > .05 
according to table footnote)
Maas et al59 (1990) Uncontrolled opioid abuse 
versus methadone 
detoxification program
Reasons: illicit; 
detoxification
Any and specific congenital 
malformations
Congenital malformations (exposure group 
not specified): 1 pyeloureteral stenosis with 
vesicoureteral reflux and 1 VSD
Metz et al60 (2015) Methadone; 
buprenorphine; SROM; 
other opioids
Reasons: illicit; 
maintenance treatment
Any congenital malformations Congenital malformations (exposure group 
not specified): 2 infants with cleft lip and 
palate and 1 infant with trisomy 18
Meyer et al61 (2015) Methadone; buprenorphine Any congenital malformations Methadone group: 1 infant with absent hand
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Source Main Comparison 
Groups/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Reasons: maintenance 
treatment
Buprenorphine group: 1 infant with isolated 
cleft palate
Olofsson et al14 
(1983)
Mainly illicit opioids 
(intravenous heroin and 
morphine) versus mainly 
methadone
Reasons: illicit; 
maintenance treatment
Severe congenital malformations; 
specific congenital malformations
Congenital malformations (exposure group 
not specified): 1 infant with gastroschisis and 
2 infants with intracranial hemorrhage
Ramer and Lodge67 
(1975)
Methadone versus heroin 
at conception (subanalysis)
Reasons: maintenance 
treatment; illicit
Any congenital malformations Congenital malformations (exposure group 
not specified): there were no congenital 
malformations noted in any infant except for 
bilateral rudimentary extra digits on 1 infant
Reddy et al68 (1971) Methadone versus heroin
Reasons: maintenance 
treatment; illicit
Serious congenital malformations Serious congenital malformations: none
Heroin group: 3 infants developed inguinal 
hernias
Thaithumyanon et 
al75 (2005)
Heroin exposure versus 
amphetamine exposure
Reasons: illicit; not 
specified (2 heroin users 
also received methadone)
Any and specific congenital 
malformations
Heroin group: none of the infants had a 
congenital malformation
Amphetamine group: 5 infants with congenital 
malformations; 1 each of large nevus 
flammeus; pigmented nevus; genu recurvatum 
(vertex presentation infant); down syndrome; 
and congenital heart disease (hypoplastic right 
ventricle)
Welle-Strand et al82 
(20 1 3)
Buprenorphine versus 
methadone
Reasons: maintenance 
treatment
Any and specific congenital 
malformations
Buprenorphine group: 1 each of spina bifida 
and gastroschisis
Methadone group: none of the infants had a 
congenital malformation
SROM, slow-release oral morphine; TCA, tricyclic antidepressant.
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TABLE 5
Large Descriptive Studies (≥100 Participants) on Prenatal Opioid Exposure and Congenital Malformations (n 
= 7)
Source Opioid Exposures/Reasons for 
Opioid Exposure
Congenital Malformations Main Findings
Blinick et al37 
(1973)
Methadone; heroin
Reasons: illicit; maintenance 
treatment
Any congenital malformation None of the infants had a congenital 
malformation
Blumenthal et al38 
(1973)
Heroin
Reasons: illicit
Any congenital malformation Heroin-exposed: the prevalence of 
congenital malformations was 12.7 per 
1000 live births
All live births (New York City): the 
prevalence of congenital malformations 
was 10 per 1000 live births
Davis and 
Chappel44 (1973)
Methadone; heroin
Reasons: illicit; maintenance 
treatment
Any congenital malformation 4 congenital malformations were noted 
overall; 2 of which were exposed to 
methadone at conception. The authors 
noted that the findings are inconclusive 
in regards to teratogenic and toxigenic 
effects
Harper et al49 
(1974)
Methadone; heroin Reasons: illicit; 
maintenance treatment
Any and specific congenital 
malformations
Congenital malformations (specific 
exposure not specified): 1 each of 
diaphragmatic hernia, bifid thoracic 
vertebrae, and polydactyly
Kivisto et al54 
(2015)
Buprenorphine
Reasons: illicit, maintenance 
treatment
Any and major congenital 
malformations
Congenital malformations noted: 1 
each of pulmonary artery stenosis, 
VSDs, multiple VSD, primary 
vesicoureteral reflux grade III, primary 
vesicoureteral reflux grade III–IV + 
hydronephrosis, duplex thumb + left-
sided duplex urinary collecting system, 
palatal cleft and ankyloglossia, Pierre 
Robin syndrome + undescended 
testicle, microtia + stenotic external ear 
canal, tetralogy of Fallot + bilateral 
inguinal hernias + multiple skeletal 
anomalies + thymic aplasia 
(additionally 1 boy had mild 
hypospadias)
Major congenital malformations: 5 of 
the 10 infants noted above had a major 
anomaly with functional or cosmetic 
significance
Study infants had slightly more major 
anomalies than newborns on average in 
the general population (3.4%)
Miles et al62 (2007) Methadone only; methadone + illicit 
substances (ie, cannabis, heroin, 
benzodiazepines, crack/cocaine, 
amphetamines, codeine, and 
dihydrocodeine)
Reasons: illicit; maintenance 
treatment
Any and specific congenital 
malformations
Congenital malformations (specific 
exposure not specified): 2 children 
were diagnosed with cleft palates; there 
were no cases of microcephaly
Newman64 (1973) Methadone
Reasons: maintenance treatment
Specific congenital malformations Congenital malformations noted: 3 
infants had heart murmursa; 1 hernia; 1 
bilateral foot deformity; 1 imperforate 
anus; and 1 esophageal malformation
There was no predominance of 
complications in any ethnic or 
methadone dosage group
a
Heart murmurs are not generally considered a congenital malformation.
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